Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
Recruiting
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Clinical Site 5, Birmingham, Alabama +14 locations
Conditions: Atopic Dermatitis
Mental Health App for Cancer Survivors Study
Recruiting
The goal of this clinical trial is to adapt a mental health digital app to treat depression among head and neck cancer patients and survivors. Participants will download and use the digital mental health app for a 6-week period, and will complete related surveys.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
05/29/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Head and Neck Cancer, Head and Neck Cancers, Depression
A Study of S-740792 in Healthy Adult Study Participants
Recruiting
This is a 3-part study of S-740792 in healthy adult participants. Part 1 (single-ascending-dose and food effect) will investigate the safety, tolerability, and pharmacokinetics (PK) of S-740792. Part 2 (multiple-ascending-dose and drug-drug interaction) will investigate the safety, tolerability, and PK of S-740792, in addition, the effect of multiple doses of S-740792 on the PK of midazolam. Part 3 will investigate the relative bioavailability of S-740792 tablet compared to S-740792 suspension a... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/29/2025
Locations: Fortrea Clinical Research Unit, Inc., Daytona Beach, Florida
Conditions: Healthy Participants
Description of Patients With Type 1 Diabetes Treated With Teplizumab
Recruiting
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia and symptoms. Stage 2 T1D includes the presence of islet autoantibodies and dysglycemia, also with no symptoms. Stage 3 T1D includes presence of islet autoantibodies, overt hyperglycemia, and symptoms... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/29/2025
Locations: Atlanta Diabetes Associates, Atlanta, Georgia +4 locations
Conditions: Type 1 Diabetes
UW Undiagnosed Genetic Diseases Program
Recruiting
The primary purpose of this study is to discover new disease genes for rare Mendelian disorders and its secondary purpose include diagnosing people with rare genetic disorders that have not been previously diagnosed through conventional clinical means, learning more about the pathobiology of genetic disorders, and developing novel diagnostic technologies and analytics. 500 participants with undiagnosed and suspected genetic disorders will be recruited.
Gender:
ALL
Ages:
100 years and below
Trial Updated:
05/29/2025
Locations: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
Conditions: Rare Diseases, Genetic Disease, Undiagnosed Disease
Vestibulopathy, Imbalance, and Gait Disturbances in Parkinson Disease
Recruiting
This study investigates whether vestibular (inner ear) dysfunction is a cause for poor balance in Parkinson Disease (PD), and whether inner ear stimulation with a small device may improve balance. This study will involve clinical testing, brain imaging, and an interventional treatment device for symptoms.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
05/29/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Parkinson Disease
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Recruiting
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab as measured by T1 Gadolinium (Gd)-enhancing lesions and pharmacokinetics in participants with Relapsing Multiple Sclerosis (RMS). The study consists of 2 parts: Part A is single-armed and open-label and Part B is randomized, double-blind, placebo-controlled.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/29/2025
Locations: TG Therapeutics Investigational Trial Site, Birmingham, Alabama +33 locations
Conditions: Relapsing Multiple Sclerosis
Hypermobile Ehlers-Danlos Syndrome - Transcutaneous Auricular Neuromodulation
Recruiting
Investigate whether at-home transcutaneous auricular VNS (tAN: transcutaneous auricular neurostimulation) improves a battery of nine key physical and psychological symptoms of a group of hEDS (Hypermobile Ehlers-Danlos Syndrome \& Hypermobile Spectrum Disorder) patients (n=30) using a randomized, double blind, sham controlled design. The study team will collect clinical measures at baseline, after a two-week double-blind intervention phase, after a following two-week open-label phase and finally... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/29/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Hypermobile Ehlers-Danlos Syndrome, Hypermobile Spectrum Disorder, Ehlers-Danlos Syndrome
Adolescent Outcomes of Post-operative Opioid EXposure
Recruiting
The goal of this observational study is to examine the factors associated with the transition from medical exposure to opioids with "signposts" of future opioid use disorder among adolescent surgical patients. The main question aims to identify factors (moderators, mediators, and covariates) associated with risk factors for opioid use disorder (ROUD) in the 12 months following major surgery with opioid exposure among adolescents aged 12-17. Participants will be asked to complete electronic surve... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/29/2025
Locations: Children's Hospital Colorado, Aurora, Colorado +4 locations
Conditions: Opioid Use Disorder, Pain, Chronic
Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell Cancer
Recruiting
The purpose of this research is to assess the safety and evaluate the potential of the Multispectral Optoacoustic Tomography (MSOT) device to more precisely identify and assess the neck lymph nodes which might be affected in patients with metastatic head and neck squamous cell carcinomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Head and Neck Squamous Cell Carcinoma
PREVENT HPV-Related Cancers Trial
Recruiting
This study will serve as one of the first to develop and test the effectiveness of strategies to promote HPV vaccination among diverse rural parents and caregivers of children ages 9-17 years in the Mountain West. Once implemented into practice, our intervention could significantly reduce disparities in the burden of HPV-associated cancers among rural populations in the United States. The proposed study will assess the effectiveness of clinic-based outreach to increase vaccination rates for HPV... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Sea Mar Community Health Centers, Seattle, Washington
Conditions: HPV Vaccination, Uptake Vaccination, Series Completion
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
Recruiting
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Modena Allergy & Asthma Clinical Research - La Jolla, La Jolla, California +5 locations
Conditions: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria